종양 NGS 시장 : 세계 시장 예측(2026-2032년)

The Oncology NGS Market is projected to grow by USD 1,389.80 million at a CAGR of 13.33% by 2032.

Oncology next-generation sequencing (NGS) has become a foundational technology in precision oncology, enabling comprehensive genomic profiling of tumors to identify clinically relevant alterations, support therapy selection, stratify patients for clinical trials, and monitor disease evolution. Unlike single-gene assays, oncology NGS can evaluate multiple biomarkers in parallel, including single nucleotide variants, insertions and deletions, copy number alterations, gene fusions, microsatellite instability, tumor mutational burden, homologous recombination deficiency, and emerging epigenomic or transcriptomic signatures, depending on assay design. This breadth is increasingly important as cancer care moves toward biomarker-driven treatment pathways across lung cancer, breast cancer, colorectal cancer, prostate cancer, hematologic malignancies, and rare tumor types.

The oncology NGS landscape is shaped by rising adoption of comprehensive genomic profiling, broader use of liquid biopsy, increasing availability of targeted therapies and immunotherapies, and growing integration of genomic data into molecular tumor boards. Clinical utility is strongest when NGS results are linked to evidence-based interpretation, standardized reporting, quality-controlled laboratory workflows, and access to appropriate therapies or trials. At the same time, implementation remains uneven because of reimbursement complexity, tissue adequacy challenges, variable test turnaround times, disparities in genomic testing access, and the need for robust bioinformatics infrastructure. For healthcare systems, laboratories, payers, and life sciences stakeholders, the strategic priority is no longer whether oncology NGS is valuable, but how to deploy it consistently, equitably, and responsibly across the cancer care continuum.

Transformative Shifts Reshaping the Oncology NGS Landscape

The oncology NGS environment is undergoing transformative shifts as testing moves from late-line, tumor-specific use toward broader applications at diagnosis, relapse, and minimal residual disease assessment. Comprehensive genomic profiling is increasingly embedded in clinical guidelines for several advanced cancers, especially non-small cell lung cancer, where multiple actionable biomarkers influence treatment selection. Similar momentum is visible in breast, ovarian, colorectal, prostate, thyroid, melanoma, and hematologic cancers, where genomic insights help identify targeted therapy options, hereditary cancer implications, and trial eligibility.

Liquid biopsy is one of the most significant shifts, offering a less invasive route to detect circulating tumor DNA when tissue is limited, inaccessible, or insufficient. It is also supporting resistance monitoring and molecular relapse detection, although sensitivity varies by tumor type, disease burden, assay methodology, and sample handling. Another major transition is the expansion from DNA-only panels to integrated multi-omics approaches that combine DNA, RNA, methylation, fragmentomics, proteomics, or immune profiling to improve detection of fusions, expression signatures, and complex biomarkers. Meanwhile, decentralized and hybrid testing models are emerging, with some health systems building in-house NGS capabilities while others rely on reference laboratories for scale, assay breadth, and specialized interpretation.

Regulatory and clinical evidence expectations are also becoming more stringent. Laboratories must demonstrate analytical validity, clinical validity, and clinical utility while maintaining compliance with quality standards, data privacy obligations, and evolving companion diagnostic requirements. The future of oncology NGS will be defined by interoperability, faster turnaround, longitudinal testing, equitable access, and the ability to translate complex genomic findings into actionable cancer treatment decisions.

Cumulative Impact of Artificial Intelligence on Oncology NGS

Artificial intelligence is becoming a cumulative force across the oncology NGS value chain, improving how genomic data are generated, interpreted, reported, and applied in clinical decision-making. In laboratory workflows, AI-assisted quality control can help identify sequencing artifacts, sample contamination, coverage gaps, and variant-calling inconsistencies. In bioinformatics, machine learning methods are increasingly used to support variant classification, structural variant detection, copy number analysis, fusion discovery, tumor purity estimation, and prioritization of clinically actionable alterations.

The greatest impact of AI in oncology NGS is emerging at the interpretation layer, where the volume and complexity of molecular findings can exceed manual review capacity. AI-enabled knowledge systems can map variants to curated evidence, clinical guidelines, drug labels, resistance mechanisms, and clinical trial eligibility criteria. Natural language processing can assist in extracting information from pathology reports, electronic health records, scientific literature, and trial registries, supporting more complete molecular tumor board review. In liquid biopsy and minimal residual disease applications, AI models may improve signal detection by integrating genomic patterns with fragment size, methylation markers, and longitudinal patient data.

However, AI adoption in oncology NGS must be governed carefully. Algorithms require transparent validation, representative training data, bias monitoring, version control, and explainable outputs suitable for clinical review. AI should augment, not replace, molecular pathologists, oncologists, geneticists, and laboratory professionals. Its long-term value will depend on clinical-grade evidence, reproducibility across populations, secure data infrastructure, and integration into regulated workflows that protect patient privacy while enabling precision oncology at scale.

Key Regional Insights Across the Oncology NGS Ecosystem

Asia-Pacific is advancing rapidly in oncology NGS adoption as cancer incidence, national precision medicine initiatives, and expanding sequencing infrastructure drive clinical demand. China, Japan, South Korea, India, Australia, and Singapore are strengthening genomic oncology capabilities through hospital-based testing, research networks, and regulatory pathways for companion diagnostics. The region shows strong momentum in lung cancer genomics, hereditary cancer testing, and liquid biopsy, though access varies widely between urban academic centers and underserved areas.

Europe is shaped by strong public health systems, cross-border research initiatives, national genomic medicine programs, and regulatory focus on in vitro diagnostics, data protection, and clinical evidence. Countries such as Germany, France, the United Kingdom, Italy, and Spain are expanding genomic testing through national or regional programs while addressing harmonization of reimbursement, laboratory standards, and molecular tumor board integration. North America remains one of the most mature regions for oncology NGS because of guideline-driven biomarker testing, established laboratory accreditation frameworks, broad clinical trial activity, advanced oncology networks, and growing payer engagement with comprehensive genomic profiling. The United States is particularly influential in tumor-agnostic biomarker adoption, companion diagnostic development, and real-world evidence generation, while Canada continues to expand provincial genomic testing programs with an emphasis on equitable access and health system integration.

Latin America is experiencing gradual expansion in oncology NGS, supported by increasing awareness of precision oncology, stronger private-sector testing availability, and regional oncology collaborations. Brazil and Mexico are central to regional progress, but reimbursement limitations, fragmented healthcare systems, limited molecular pathology capacity, and uneven access to targeted therapies continue to affect routine implementation. Africa is at an earlier stage of oncology NGS deployment, with access concentrated in select academic, private, and international collaboration settings. Major priorities include pathology capacity, sample logistics, sequencing infrastructure, workforce training, ethical genomic governance, and inclusion of African genomic diversity in cancer research. The Middle East is investing in precision medicine infrastructure, with GCC countries emphasizing advanced oncology centers, genomic databases, and tertiary care capabilities. Adoption is strongest in specialized hospitals, supported by government healthcare modernization strategies, although workforce development and standardized reimbursement remain important.

Key Group Insights for Oncology NGS Adoption

NATO countries overlap substantially with advanced North American and European healthcare systems, where oncology NGS adoption is supported by laboratory quality frameworks, data security priorities, regulated clinical pathways, and strong biomedical research infrastructure. The G7 countries collectively influence oncology NGS standards through advanced regulatory systems, reimbursement models, clinical guideline development, academic research, and large-scale cancer genomics initiatives. These economies are particularly important in companion diagnostic alignment, molecular tumor board maturity, real-world evidence development, and integration of comprehensive genomic profiling into cancer care.

BRICS countries represent a diverse and strategically significant group for oncology NGS. China and India are expanding sequencing capacity and clinical genomics programs, Brazil is strengthening precision oncology access in Latin America, Russia maintains specialized oncology and genetics capabilities despite system-level constraints, and South Africa plays an important role in genomic research and regional oncology capacity building. The European Union provides a highly structured environment for oncology NGS through regulatory oversight, cross-country research networks, health technology assessment, cancer mission initiatives, and data governance frameworks. The EU's emphasis on interoperability, evidence generation, and equitable cancer care supports broader adoption, although reimbursement decisions and implementation models remain country-specific.

ASEAN is emerging as an important growth arena for oncology NGS as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines expand cancer diagnostics infrastructure at different speeds. Singapore is a regional leader in genomic medicine, while broader ASEAN adoption is influenced by affordability, laboratory capacity, clinician education, and access to targeted oncology therapies. The GCC is prioritizing oncology NGS within broader precision medicine and healthcare transformation strategies. Countries in the group are investing in advanced cancer centers, genomic data initiatives, and high-acuity tertiary care, creating opportunities for comprehensive genomic profiling and liquid biopsy integration. Across all groups, the decisive factors are reimbursement clarity, clinical utility evidence, workforce capability, data interoperability, and patient access to matched therapies.

Key Country Insights in Oncology NGS

China has built substantial sequencing capacity and is applying oncology NGS across lung cancer, gastrointestinal cancers, hereditary cancer, and liquid biopsy, supported by domestic innovation and expanding clinical evidence generation. The United States leads in oncology NGS implementation through extensive biomarker-driven clinical guidelines, broad availability of comprehensive genomic profiling, active clinical trial networks, and established pathways for companion diagnostics. Japan has formalized comprehensive genomic profiling within advanced cancer care pathways and emphasizes regulated testing, expert interpretation, and linkage to clinical trials. India is rapidly increasing use of oncology NGS in metropolitan cancer centers, with demand driven by rising cancer burden, private diagnostic networks, and growing clinician adoption, although affordability and reimbursement remain central barriers.

Germany benefits from strong molecular pathology expertise, certified laboratories, and reimbursement mechanisms for selected genomic applications. The United Kingdom has advanced national genomic testing infrastructure and integrated genomic laboratory networks that support standardized cancer testing. Australia has strong clinical genomics programs, population-level precision oncology initiatives, and well-developed laboratory quality systems. France has long-standing national molecular oncology networks and continues to strengthen comprehensive genomic profiling through structured public programs. South Korea is advancing oncology NGS through national reimbursement mechanisms for selected panels, technologically sophisticated hospitals, and strong integration of molecular diagnostics into cancer care.

Italy and Spain are expanding tumor genomic testing through regional health systems, molecular tumor boards, and increasing alignment with European oncology guidelines. Canada is expanding access through provincial health systems and national precision oncology collaborations, with an emphasis on evidence-based reimbursement and equitable testing. Russia has oncology genetics capabilities in major centers, but access and integration vary across regions. Brazil is the most prominent oncology NGS environment in Latin America, supported by large cancer centers, academic research activity, and rising precision oncology awareness, though public-sector access remains uneven. Mexico is increasing adoption in major cancer centers, particularly for lung, breast, colorectal, and hereditary cancer applications, while broader access remains shaped by payer fragmentation and infrastructure gaps.

Actionable Recommendations for Oncology NGS Industry Leaders

Industry leaders should prioritize clinical-grade evidence generation that demonstrates how oncology NGS improves treatment selection, trial matching, disease monitoring, and patient outcomes across specific tumor types and care settings. Laboratories and healthcare providers should streamline pre-analytical workflows to reduce tissue insufficiency, standardize sample handling, and improve turnaround times. Expanding reflex testing protocols for guideline-supported biomarkers can reduce delays and ensure that actionable genomic information is available before treatment decisions are made.

Stakeholders should invest in interoperable bioinformatics platforms, structured reporting, and decision support tools that connect genomic findings with therapy labels, guidelines, resistance data, and clinical trial options. Payers and health systems should develop reimbursement policies based on clinical utility, test quality, and appropriate use criteria, while also supporting equitable access for underserved populations. Oncology networks should strengthen molecular tumor boards, genetic counseling pathways, and clinician education to ensure that NGS results are interpreted correctly and translated into care.

For liquid biopsy and minimal residual disease applications, leaders should define clear use cases, validation standards, and longitudinal testing protocols. Data governance must be treated as a strategic priority, with secure infrastructure, consent frameworks, privacy safeguards, and responsible AI oversight. Organizations that combine validated assays, robust interpretation, real-world evidence, and patient-centered access models will be best positioned to advance precision oncology responsibly.

Research Methodology for Oncology NGS Analysis

This executive summary is developed using a structured secondary research methodology focused on verified, data-backed insights from authoritative sources relevant to oncology NGS and precision cancer diagnostics. The research approach emphasizes peer-reviewed scientific literature, clinical practice guidelines, regulatory publications, public health agency resources, professional oncology and pathology society guidance, health technology assessment documents, and publicly available information from national genomic medicine initiatives. Priority is given to sources that address analytical validity, clinical validity, clinical utility, reimbursement considerations, regulatory requirements, biomarker adoption, and regional implementation trends.

The methodology includes triangulation across multiple evidence categories to avoid reliance on single-source conclusions. Clinical insights are assessed in relation to established cancer care pathways, biomarker testing recommendations, companion diagnostic use, and molecular tumor board practices. Regional, group, and country-level insights are synthesized by evaluating healthcare infrastructure, genomic medicine policies, laboratory capacity, reimbursement environments, data governance maturity, and access to targeted therapies or immunotherapies. No market sizing, market share, or forecasting assumptions are used. The analysis is designed to provide decision-ready strategic intelligence for stakeholders seeking to understand oncology NGS adoption dynamics, implementation barriers, and evidence-based opportunities across global healthcare systems.

Conclusion: Oncology NGS as a Core Engine of Precision Oncology

Oncology NGS is redefining cancer diagnostics by enabling a more comprehensive, precise, and clinically actionable understanding of tumor biology. Its role now extends beyond identifying individual mutations to supporting integrated cancer management through comprehensive genomic profiling, liquid biopsy, therapy resistance monitoring, hereditary risk assessment, and clinical trial matching. As the evidence base grows, oncology NGS is becoming increasingly embedded in precision oncology programs, but its impact depends on equitable access, high-quality testing, validated interpretation, and alignment with treatment availability.

The next phase of oncology NGS will be shaped by multi-omics integration, AI-assisted interpretation, improved liquid biopsy performance, stronger regulatory oversight, and deeper use of real-world evidence. Regions and health systems that invest in laboratory quality, reimbursement clarity, clinician education, data interoperability, and responsible governance will be better positioned to translate genomic insights into measurable clinical value. For industry leaders, the strategic imperative is to move beyond test availability and focus on building reliable, scalable, and patient-centered precision oncology ecosystems that connect genomic information to better cancer care decisions.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Oncology NGS Market, by Product Type

• 7.1. Introduction
• 7.2. Instruments
• 7.3. Reagents & Consumables
  • 7.3.1. Library Preparation Kits
  • 7.3.2. Sequencing Reagents
  • 7.3.3. Target Enrichment Kits
• 7.4. Services
  • 7.4.1. Bioinformatics & Data Analysis Services
  • 7.4.2. Clinical Reporting & Interpretation Services

8. Oncology NGS Market, by Cancer Type

• 8.1. Introduction
• 8.2. Solid Tumors
  • 8.2.1. Breast Cancer
  • 8.2.2. Lung Cancer
  • 8.2.3. Colorectal Cancer
  • 8.2.4. Prostate Cancer
  • 8.2.5. Ovarian Cancer
  • 8.2.6. Melanoma
• 8.3. Hematologic Malignancies
  • 8.3.1. Leukemia
  • 8.3.2. Lymphoma
  • 8.3.3. Myeloma

9. Oncology NGS Market, by Technology

• 9.1. Introduction
• 9.2. Whole Genome Sequencing
• 9.3. Whole Exome Sequencing
• 9.4. Targeted Sequencing & Resequencing

10. Oncology NGS Market, by Sample Type

• 10.1. Introduction
• 10.2. Tissue Samples
  • 10.2.1. Formalin-Fixed Paraffin-Embedded Tissue
  • 10.2.2. Fresh Frozen Tissue
• 10.3. Liquid Biopsy Samples
  • 10.3.1. Plasma
  • 10.3.2. Serum
  • 10.3.3. Circulating Tumor Cells

11. Oncology NGS Market, by Workflow Stage

• 11.1. Introduction
• 11.2. Pre-Sequencing
• 11.3. Sequencing
• 11.4. Data Analysis

12. Oncology NGS Market, by Application

• 12.1. Introduction
• 12.2. Clinical Diagnostics
  • 12.2.1. Solid Tumor Profiling
  • 12.2.2. Hematologic Malignancy Profiling
  • 12.2.3. Germline Cancer Predisposition Testing
  • 12.2.4. Minimal Residual Disease Monitoring
  • 12.2.5. Companion Diagnostics
• 12.3. Research
  • 12.3.1. Oncology Biomarker Discovery
  • 12.3.2. Tumor Heterogeneity Studies
  • 12.3.3. Resistance Mechanism Studies
• 12.4. Drug Development
• 12.5. Liquid Biopsy
  • 12.5.1. Early Cancer Detection
  • 12.5.2. Treatment Response Monitoring
  • 12.5.3. Recurrence Surveillance

13. Oncology NGS Market, by End User

• 13.1. Introduction
• 13.2. Academic & Research Institutions
• 13.3. Hospitals & Cancer Centers
  • 13.3.1. Oncology Departments
  • 13.3.2. Pathology Laboratories
• 13.4. Clinical Diagnostic Laboratories
• 13.5. Pharmaceutical & Biotechnology Companies
• 13.6. Contract Research Organizations

14. Oncology NGS Market, by Region

• 14.1. Asia-Pacific
• 14.2. Europe
• 14.3. North America
• 14.4. Latin America
• 14.5. Africa
• 14.6. Middle East

15. Oncology NGS Market, by Group

• 15.1. NATO
• 15.2. G7
• 15.3. BRICS
• 15.4. European Union
• 15.5. ASEAN
• 15.6. GCC

16. Oncology NGS Market, by Country

• 16.1. China
• 16.2. United States
• 16.3. Japan
• 16.4. India
• 16.5. Germany
• 16.6. United Kingdom
• 16.7. Australia
• 16.8. France
• 16.9. South Korea
• 16.10. Italy
• 16.11. Canada
• 16.12. Russia
• 16.13. Brazil
• 16.14. Mexico
• 16.15. Spain

17. Competitive Landscape

• 17.1. Market Share Analysis, 2025
• 17.2. FPNV Positioning Matrix, 2025
• 17.3. Market Concentration Analysis, 2025
  • 17.3.1. Concentration Ratio (CR)
  • 17.3.2. Herfindahl Hirschman Index (HHI)
• 17.4. Recent Developments & Impact Analysis, 2025
• 17.5. Product Portfolio Analysis, 2025
• 17.6. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Agilent Technologies, Inc.
• 18.2. BGI Group
• 18.3. Bio-Rad Laboratories, Inc.
• 18.4. Burning Rock Dx
• 18.5. Creative Biogene
• 18.6. Eurofins Scientific S.E.
• 18.7. Exact Sciences Corporation
• 18.8. F. Hoffmann-La Roche Ltd.
• 18.9. Genecast Group Inc.
• 18.10. Guardant Health, Inc.
• 18.11. Hologic, Inc.
• 18.12. Illumina, Inc.
• 18.13. Invivoscribe, Inc.
• 18.14. Macrogen, Inc.
• 18.15. Myriad Genetics, Inc.
• 18.16. Natera, Inc.
• 18.17. Oxford Nanopore Technologies plc.
• 18.18. Pacific Biosciences of California, Inc.
• 18.19. PerkinElmer Inc.
• 18.20. Personalis, Inc.
• 18.21. Promega Corporation
• 18.22. Qiagen N.V.
• 18.23. SOPHiA GENETICS.
• 18.24. Takara Bio Inc.
• 18.25. Thermo Fisher Scientific, Inc.
• 18.26. Twist Bioscience Corporation